VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP POWDER FOR SOLUTION

Ország: Kanada

Nyelv: angol

Forrás: Health Canada

Vedd Meg Most

Letöltés Termékjellemzők (SPC)
26-10-2020

Aktív összetevők:

VANCOMYCIN (VANCOMYCIN HYDROCHLORIDE)

Beszerezhető a:

GENERIC MEDICAL PARTNERS INC

ATC-kód:

J01XA01

INN (nemzetközi neve):

VANCOMYCIN

Adagolás:

500MG

Gyógyszerészeti forma:

POWDER FOR SOLUTION

Összetétel:

VANCOMYCIN (VANCOMYCIN HYDROCHLORIDE) 500MG

Az alkalmazás módja:

INTRAVENOUS

db csomag:

10X10ML

Recept típusa:

Prescription

Terápiás terület:

GLYCOPEPTIDES

Termék összefoglaló:

Active ingredient group (AIG) number: 0131315003; AHFS:

Engedélyezési státusz:

APPROVED

Engedély dátuma:

2014-12-18

Termékjellemzők

                                PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP
500 mg and 1 g of Vancomycin (as Vancomycin Hydrochloride)
per vial
Sterile Lyophilized
Powder for Solution
ANTIBIOTIC
Generic Medical Partners Inc.
Date of Revision:
1500 Don Mills Road, Suite 406
October 26, 2020
Toronto, ON M3B 3K4
Control No.: 239577
2
PR
VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP
ANTIBIOTIC
ACTIONS
The inhibition
of cell wall synthesis has been shown by _ in vitro _studies to be
responsible for the
bactericidal action of vancomycin against many gram-positive bacteria.
There is also evidence
that RNA synthesis is selectively inhibited
and the permeability of the cell membrane is altered
by vancomycin.
INDICATIONS AND CLINICAL USE
Vancomycin Hydrochloride
for Injection USP is indicated in the therapy of severe or life-
threatening staphylococcal infections in patients who cannot receive
or have failed to respond to
the penicillins or cephalosporins, or who have infections with
staphylococci resistant to other
antibiotics,
including methicillin.
To reduce the development of drug-resistant bacteria and maintain the
effectiveness of
Vancomycin Hydrochloride
for Injection USP and other antibacterial drugs, Vancomycin
Hydrochloride for Injection USP should be used only to treat
infections that are proven or
strongly suspected to be caused by susceptible bacteria. When culture
and susceptibility
information
are available, they should be considered in selecting or modifying
antibacterial
therapy. In the absence of such data, local epidemiology
and susceptibility patterns may
contribute to the empiric selection of therapy.
In the treatment of staphylococcal endocarditis, vancomycin has been
used successfully alone.
In other infections due to staphylococci, including
osteomyelitis, pneumonia,
septicemia and soft-
tissue infections, vancomycin's effectiveness has been documented.
Antibiotics are used as
adjuncts to appropriate surgical measures when staphylococcal
infections are localized and
purulen
                                
                                Olvassa el a teljes dokumentumot
                                
                            

Dokumentumok más nyelveken

Termékjellemzők Termékjellemzők francia 26-10-2020

A termékkel kapcsolatos riasztások keresése